CinnoPar® is a man-made form of a hormone called parathyroid that exists naturally in the body. CinnoPar® increases bone density and increases bone strength to help prevent fractures.

سینوپار® در جهت کاهش خطر شکستگی استخوانها ، به ویژه استخوان لگن در خانم های مبتلا به پوکی استخوان پس از سن یائسگی استفاده می شود. همچنین در کاهش ریسک شکستگی استخوانها در مردان و زنان با پوکی استخوان اولیه یا هایپوگنادیال و پوکی استخوان ناشی از مصرف مداوم گلکوکورتیکوئیدها کاربرد دارد.

CinnoPar ® is indicated for treatment of glucocorticoid-induced osteoporosis, osteoporosis in men and osteoporosis in postmenopausal women who are at high risk for fractures. CinnoPar ® is contraindicated in patients who have hypersensitivity to teriparatide or …

سينوپار باعث تحریک ساخت استخوان، افزايش تراکم مواد معدني استخوانی و افزايش استحکام استخوان می شود. سينوپار می تواند تعداد شکستگی ها در ستون فقرات و سایر استخوان ها را در خانم هاي یائسه مبتلا به پوكي استخوان کاهش دهد. سينوپار هم در مردان و هم در زنان يائسه مبتلا به پوكي استخوان که در معرض ریسک بالایی برای شکستگی قرار دارند؛ استفاده می گردد.

• CinnoPar® is recombinant endogenous PTH (1-34) produced by CinnaGen Co. • CinnoPar® is used for treatment of osteoporosis in postmenopausal women, who are at high risk for fractures. • CinnoPar® is used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fractures. • CinnoPar®

CinnoPar® can be considered as a good alternative therapy for Forteo® in postmenopausal osteoporotic women due to its comparable efficacy and safety properties.

May 31, 2021 · The safety of teriparatide has been studied in various phase III and phase IV trials. However, a postmarketing study of the biosimilar of teriparatide, CinnoPar ®, has not been conducted on Iranian patients.

Changes in BMD T-score from pre-to post-treatment with biosimilar teriparatide: A single-arm, multi-center study.

The study aimed to use Cinnopar to improve and accelerate rate of the healing process and reduce complications of femoral neck fractures in people aged 40 to 60 years. Methods: In the study, 34 femoral neck fracture patients were included in two groups as receiving Cinnopar group(N=17) and not receiving Cinnopar group(N=17). The patients were ...

CinnoPar stimulates bone formation and increases bone mineral density and bone strength. It can also reduce the number of fractures of the spine and other bones in postmenopausal women with osteoporosis.